CELL CYCLE AND REGULATION

Cell Cycle Products (click for new additions to this section)

CELL SYNCHRONIZATION REAGENTS

TABLE 8. CELL SYNCHRONIZATION REAGENTS

See also D.T. Hung et al. (1996)³¹.

CC-100
2-Aminopurine (2-AP)
98%, MW=135.1 [452-06-2] Storage: RT
A purine analog that can override multiple cell cycle checkpoints. May be used to override drug-induced cell cycle blocks³². It is a selective protein kinase inhibitor that can inhibit p58 PITSLREb1, a p34^cdc2-related protein kinase, in vivo³³.
100 mg
500 mg

CC-101
Aphidicolin
98%, MW=338.5 [38966-21-1] Storage: -20°C
A diterpene fungal metabolite that blocks cell cycle at early S-phase. Reversible inhibitor of DNA polymerase a and d^34,35
1 mg
5 x 1mg

CC-103
Methotrexate
Amethopterin; 4-Amino-10-methylfolic acid
98%, MW=454.4 [59-05-2] Storage: -20°C
Folic acid antagonist. Potent inhibitor of dihydrofolate reductase. Arrests cell cycle in S^36,37. Induces apoptosis³⁸. Clinically useful anticancer agent.
100 mg
500 mg

CC-102
L-Mimosine
-[N-(3-hydroxy-4-pyridone)]--aminopropionic acid
99%, MW=198.2 [500-44-7] Storage: RT
A rare plant amino acid that reversibly blocks the cell cycle at G1-phase. Inhibits the hydroxylation of deoxyhypusine and thus inhibits eukaryote initiation factor 5-A (eIF5-A)³⁹. Also chelates iron via the Kojic acid metal-binding domain.
500 mg
2 g

CC-200
Olomoucine
99%, MW=298.3 [101622-51-9] Storage: -20°C
Olomoucine is a new purine derivative which acts as a potent and selective inhibitor of p34^cdc2/cyclin B and related kinases. It acts by competing for the ATP binding domain of the kinase. Of 35 protein kinases tested, olomoucine inhibited p33^cdk2/cyclin A, p33^cdk2/cyclin E, p34^cdc2/cyclin B, p33^cdk5/p35 and erk1 with IC₅₀s of 7, 7, 7, 3 and 25 µM respectively⁴⁰. The related kinases p34^cdk4/cyclin D and p40^cdk6/cyclin D3 were not inhibited or were less sensitive to olomoucine, IC₅₀s > 1000 and 250 µM respectively. PKC, PKA, PKG, CaM kinase II, MLC kinase, CK2, EGFr tyrosine kinase, p56^lck, p56^lyn, p60^c-src, v-abl and insulin receptor tyrosine kinase are not inhibited or are weakly inhibited at 1 mM. It delays mouse oocyte maturation and inhibits the growth of a variety of human cell lines including Rhabdomyosarcoma cell line Rh1, Rh18, Rh28 and Rh30; MCF-7, KB-3-1 and their adriamycin-resistant counterparts (IC₅₀=18-86 µM)⁴¹. It inhibits DNA synthesis in interleukin-2-stimulated T lymphocytes and triggers a G1 arrest similar to interleukin-2 deprivation⁴².
5 mg
25 mg
NEW LOWER PRICE

CC-205
Roscovitine
95%, MW=354.5, Storage: -20°C
Potent inhibitor of p34^cdc2/cyclin B kinase (IC₅₀= 0.2 µM)^43,44.
1 mg
5 mg

CC-104
Tunicamycin
99%, Ave. MW=840.0 [11089-65-9] Storage: -20?br> Mixture of tunicamycins A, B, C and D. Inhibits protein glycosylation⁴⁵. Arrests cell cycle in late G1^46,47.
10 mg
5 x 10 mg

PROTEINS

SE-128
p34^cdc2/cyclin B (human, recombinant)
Protein serine/threonine kinase
>90% by SDS-PAGE, MW=55 kDa, Storage: -70°C
Human p34^cdc2 kinase and human cylin B coexpressed in a baculovirus expression system. The enzyme complex is activated by CAK (cyclin-activating kinase) phosphorylation. Supplied at 2 kU/ml. One unit will transfer 1 pmol phosphate per min at 30°C to histone H1 substrate. Useful for phosphorylation of target enzymes and other substrates of p34^cdc2/cyclin B^48,49.
100 U

PEPTIDES

P-103
Casein kinase II (198-215), cdk (cell-cycle dependent kinase) substrate
Gln-Leu-Gln-Leu-Gln-Ala-Ala-Ser-Asn-Phe-Lys-Ser-Pro-Val-Lys-Thr-Ile-Arg
>97%, MW=2028.1, Storage: -20°C
Sequence contains CKII autophosphorylation site plus p34^cdc2 consensus phosphorylation site Ser-209⁵⁰. Used as a cdc2 substrate (0.25 mM) and also a competitive inhibitor with ID₅₀=50 µM for inhibition of apoptosis induced by perforin and fragmentin-2 in YAC-1 lymphoma cells (peptide A)⁵¹. Supplied lyophilized.
1 mg
5 x 1 mg

P-104
CSH103, p34^cdc2 protein kinase substrate
Ala-Asp-Ala-Gln-His-Ala-Thr-Pro-Pro-Lys-Lys-Lys-Arg-Lys-Val-Glu-Asp-Pro-Lys-Asp-Phe
>97%, MW=2406.7 [135546-44-0] Storage: -20°C
Sequence is SV40 LTag (118-138) with Ser to Ala-120 and 123 substitutions to increase specificity. Substrate is specific for p34^cdc2 and is a poor substrate for CKI, II, PKA, GSK3, PKC, CaMKII, and phosphorylase b kinase. Can be used in cell lysates using TCA/phosphocellulose assay. K_m=74 µM for active complex with cyclin B⁵².
0.5 mg
5 x 0.5 mg

P-402
PSTAIRE peptide
Glu-Gly-Val-Pro-Ser-Thr-Ala-Ile-Arg-Glu-Ile-Ser-Leu-Leu-Lys-Glu
>97%, MW=1740.9, Storage: -20°C
Cyclin-dependent protein kinase (cdk) highly conserved sequence⁵³. Causes meiotic maturation and calcium rise in starfish and Xenopus oocytes when microinjected (20 mg/ml)^54,55. Also can be used as an antibody blocking peptide⁵⁶.
1 mg
5 x 1 mg

ANTIBODIES

SA-119
Anti-p34^cdc2, cyclin-dependent kinase
Mouse monoclonal antibody. Clone 17. Immunogen: C-terminal peptide from cdc2Mm sequence⁵³. Supplied as affinity purified IgG2a, 0.1 mg/ml. Recognizes human, mouse and Xenopus C-terminal epitope. Applications: WB 1/100, IP (active in immune-complex kinase assay).
100 µg

SA-208
Anti-p34^cdc2, cyclin-dependent kinase, C-terminal
Rabbit polyclonal antibody. Immunogen: C-terminal human cdc2 peptide conjugated to KLH. Supplied as serum with sodium azide added. Recognizes human, rat and mouse cdc2 but not other cdk's^57,58. Applications: WB 1/500, IP, ELISA.
100 µl

SA-193
Anti-cdk2, cyclin-dependent kinase
Rabbit polyclonal antibody. Immunogen: C-terminal human cdk2 peptide conjugated to KLH⁵⁹. Supplied as serum with sodium azide added. Recognizes human and mouse cdk2, but not p34^cdc2. Applications: WB 1/1000, IP.
100 µl

SA-273
Anti-Cdk4
Mouse monoclonal antibody. Clone 35.1. Immunogen: Human recombinant cdk4. Supplied as purified IgG1, 0.2 mg/ml. Recognizes human, rat and mouse cdk4. Applications: WB 1 µg/ml, IP (co-immunoprecipitates D-type cyclins bound to cdk4; active in immune-complex kinase assays), IH 1/50.
100 µg

SA-260
Anti-Cyclin D1, Neutralizing antibody
Mouse monoclonal antibody. Clone DCS-6. Immunogen: Human recombinant cyclin D1. Supplied as purified IgG2a, 0.2 mg/ml. Recognizes human, monkey, rat and mouse cyclin D1. Neutralizes the activity of cyclin D1 in vivo⁶⁰. Applications: WB 1 µg/ml, IP (non-denatured), IH 1/50⁶¹.
100 µg

SA-261
Anti-Cyclin D1, Kinase-complex active
Mouse monoclonal antibody. Clone DCS-11. Immunogen: Human recombinant cyclin D1. Supplied as purified IgG2a, 0.2 mg/ml. Recognizes human, rat and mouse cyclin D1. Applications: IP (native or denatured). Co-immunoprecipitates cyclin D1-bound cdk4 and/or cdk6 kinases. Active in immune-complex kinase assays. Use SA-260 above for WB and IH.
100 µg

SA-262
Anti-Cyclin D2, Neutralizing antibody
Mouse monoclonal antibody. Clone DCS-3.1. Immunogen: Human recombinant His-tagged cyclin D2. Supplied as purified IgG2a, 0.2 mg/ml. Recognizes human, rat and mouse cyclin D2. Neutralizes the activity of cyclin D2 in vivo. Applications: WB 1-2 µg/ml, IP (inhibits cdk4/cdk6 activity).
100 µg

SA-263
Anti-Cyclin D2, Kinase-complex active
Mouse monoclonal antibody. Clone DCS-5.2. Immunogen: Human recombinant His-tagged cyclin D2. Supplied as purified IgG2b, 0.2 mg/ml. Recognizes human, rat and mouse cyclin D2. Co-immunoprecipitates cyclin D2-bound cdk4 and/or cdk6 kinases. Active in immune-complex kinase assays. Applications: WB 1-2 µg/ml, IP.
100 µg

SA-265
Anti-Cyclin D3, Kinase-complex active
Mouse monoclonal antibody. Clone DCS-28.1. Immunogen: Human recombinant cyclin D3. Supplied as purified IgG1, 0.2 mg/ml. Recognizes human cyclin D3. Co-immunoprecipitates cyclin D3-bound cdk4 and/or cdk6 kinases. Active in immune-complex kinase assays. Applications: WB 1-2 µg/ml, IP, IH 1/50.
100 µg

SA-124
Anti-Retinoblastoma protein (Rb)
Mouse monoclonal antibody. Clone 1F8. Immunogen: Retinoblastoma gene product -gal fusion protein⁶². Supplied as purified IgG1, 100 µg/ml. Recognizes human p105 Rb. Applications: WB, IF, IH 1/1000, IP.
100 µg

SA-188
Anti-Retinoblastoma protein (Rb)
Mouse monoclonal antibody. Clone mAb245. Supplied as purified IgG1, 1 mg/ml. Recognizes human, primate, rat, and mouse Rb. Epitope is human Rb (300-800). Applications: WB, IP, IF, IH^63,64.
100 µg

SA-189
Anti-Retinoblastoma protein (Rb), underphosphorylated
Mouse monoclonal antibody. Clone mAb549. Supplied as purified IgG1, 0.5 mg/ml. Recognizes fast-migrating, underphosphorylated Rb only. Epitope is human Rb (514-610). Cross-reacts with mouse. Applications: WB 1-2 µg/ml, IP.
100 µg

REFERENCES

1. J. Liu and M.N. Hall Trends Pharmacol. Sci. 1993 14 182

2. J. Liu et al. Cell 1991 66 807

3. J.M. Gudas et al. Cell Growth Differ. 1994 5 295

4. K. Keyomarsi et al. Cancer Res. 1991 51 3602

5. M. Jakobisiak et al. Proc. Natl. Acad. Sci. USA 1991 88 3628

6. J. Kunz and M.N. Hall Trends Biochem. Sci. 1993 18 334

7. W.G. Morice et al. J. Biol. Chem. 1993 268 3734

8. J. Chung et al. 1994 Nature 1994 370 71

9. C. Giardina and J.T. Lis J. Biol. Chem. 1993 268 23806

10. C.S. Rani et al. J. Biol. Chem. 1995 270 2859

11. I.K. Kim et al. FEBS Lett. 1993 321 209

12. H. Minami et al. Biochem. Biophys. Res. Commun. 1994 199 241

13. E.E. Medrano and A.B. Pardee Proc. Natl. Acad. Sci. USA 1980 77 4123

14. G. Fenteany et al. Science 1995 268 726

15. Y. Lin et al. J. Cell. Physiol. 1992 152 646

16. J. Gong et al. Cancer Res. 1994 54 3136

17. J. Gong et al. Cancer Res. 1994 54 3136

18. Y. Hoshikawa et al. Exp. Cell Res. 1994 214 189

19. K. Ishiyama et al. Tohoku J. Exp. Med. 1994 174 95

20. G. Giese et al. J. Cell Physiol. 1995 163 145

21. E. Petru et al. Gynecol. Oncol. 1995 58 48

22. F. Spinozzi et al. Leuk. Res. 1994 18 431

23. T. Nordstrom et al. Exp. Cell Res. 1992 202 487

24. A. Obinata et al. Exp. Cell Res. 1991 193 36

25. S.W. Sherwood et al. Proc. Natl. Acad. Sci. USA 1993 90 3353

26. S. Uppuluri et al. Proc. Natl. Acad. Sci. USA 1993 90 11598

27. J.C. Lee et al. J. Biol. Chem. 1975 250 9276

28. K.W. Kohn et al. J. Cell. Biochem. 1994 54 440

29. P.A. Takizawa et al. Cell 1993 73 1079

30. S.N. Martineau et al. J. Cell Biol. 1995 131 191

31. D.T. Hung et al. Chemistry & Biol. 1996 3 623

32. P.R. Andreassen and R.L. Margolis Proc. Natl. Acad. Sci. USA 1992 89 2272

33. J. Xiang et al. Biochem. Biophys. Res. Commun. 1994 199 1167

34. V. Levenson and J.L. Hamlin Nucleic Acids Res. 1993 21 3997

35. P.J. O'Dwyer et al. Cancer Res. 1994 54 724

36. V.B. Richardson et al. Cytogenet. Cell. Genet. 1994 66 126

37. S.M. Pittman et al. Exp. Cell. Res. 1994 215 263

38. L. I. Huschtscha et al. Br. J. Cancer 1996 73 54

39. H.M. Hanauske-Abel et al. Biochim. Biophys. Acta 1994 1221 115

40. J. Vesely et al. Eur. J. Biochem. 1994 224 771

41. R.T. Abraham et al. Biomed. J. 1994 1 32

42. R.T. Abraham et al. Biol. Cell 1995 83 105

43. L. Havlicek et al. J. Med. Chem. 1997 40 408

44. B. Rudolph et al. EMBO J. 1996 15 3065

45. D. Duksin and W.C. Mahoney J. Biol. Chem. 1982 257 3105

46. T.J.Langan and M.C. Slater J. Cell. Physiol. 1991 149 284

47. S. Ishii and J.J. Volpe J. Neurochem. 1987 49 1606

48. L.L. Parker et al. Proc. Natl. Acad. Sci. USA 1992 89 2917

49. S. Atherton-Fessler et al. Mol. Cell. Biol. 1993 13 1675

50. D.W. Litchfield et al. J. Biol. Chem. 1991 266 20380

51. L. Shi et al. Science 1994 263 1143

52. D.R. Marshak et al. J. Cell. Biochem. 1991 45 391

53. C.J. Norbury and P. Nurse Biochim. Biophys. Acta 1989 989 85

54. A. Picard et al. Science 1990 247 327

55. J.C. Labbe et al. Cell 1989 57 253

56. K. Kamo et al. J. Immunol. Methods 1992 156 163

57. X. Grana et al. Proc. Natl. Acad. Sci. USA 1994 91 3834

58. J. Rosenblatt et al. Proc. Natl. Acad. Sci. USA 1992 89 2824

59. J. Rosenblatt et al. Proc. Natl. Acad. Sci. USA 1992 89 2824

60. J. Lukas et al. Mol. Cell. Biol. 1995 15 2600

61. C.J. DeBoer et al. Blood 1995 86 2715

62. J. Bartek et al. Oncogene 1992 7 101

63. W.-P. Dou et al. Proc. Natl. Acad. Sci. USA 1992 89 3256

64. C.-Y. Chang et al. Cell Growth Differen. 1993 4 1057